Companies Regeneron

Regeneron

New York, New York, USA

Total Offices: 7

15,000 Total Employees

Year Founded: 1988

View Website

Jobs at Similar Companies

Similar Companies Hiring

SOPHiA GENETICS

Software • Healthtech • Biotech • Big Data • Artificial Intelligence

3 Offices

450 Employees

Pfizer

Pharmaceutical • Natural Language Processing • Machine Learning • Healthtech • Biotech • Artificial Intelligence

19 Offices

121990 Employees

Cencora

Healthtech • Logistics • Pharmaceutical

15 Offices

51000 Employees

Regeneron Company Stability & Growth

Updated on March 04, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Regeneron and has not been reviewed or approved by Regeneron.

What's the stability & growth outlook for Regeneron?

Strengths in product-led and platform-enabled growth, supported by collaboration economics and shareholder-return actions, are accompanied by meaningful regulatory and label-execution uncertainties that can shift near-term trajectory. Together, these dynamics suggest a generally resilient growth profile with outsized sensitivity to a few upcoming FDA milestones and ophthalmology lifecycle outcomes.

Positive Themes About Regeneron

Product Line Growth: The company is growing on financials and products, with momentum attributed to EYLEA HD, Libtayo, and rising Dupixent collaboration revenue alongside shareholder-return actions (dividend and buybacks) reinforcing the trend in 2024–2025.
Future-Ready Strategy: The setup for 2025–2026 includes multiple identified catalysts, including the odronextamab FDA decision (target action date July 30, 2025), further EYLEA HD label/formulation updates, and the ongoing Dupixent COPD rollout as key determinants for sustaining or accelerating growth.
Innovation-Driven Growth: A science-driven platform approach (including VelocImmune, the Regeneron Genetics Center, and advanced proteomics/genomics) is positioned as enabling rapid therapeutic discovery across multiple therapeutic areas, supporting an ongoing pipeline-led growth thesis.

Considerations About Regeneron

Weak Market Position & Pricing Challenges: Near-term commercial upside for EYLEA HD could be slower than hoped after FDA declined adding dosing beyond q16 weeks (April 2025) and later extended reviews for other HD supplements, potentially limiting competitive differentiation on durability and convenience in the near term.
Short-Term or Unsustainable Growth: The hematology bispecifics program faces regulatory pacing risk after FDA Complete Response Letters (March 2024) for odronextamab tied to confirmatory-trial enrollment, making timelines and outcomes material swing factors despite the FL BLA resubmission being accepted with a July 30, 2025 target action date.
Stagnant Revenue: Recent growth is described as modest and uneven, with full-year revenue increasing only slightly in 2025 and pressure from weakening broader EYLEA sales offset by strong performance in Dupixent collaboration revenue and EYLEA HD.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.